SynthesisVascular health and risk management2008
Next-generation drug-eluting stents in coronary artery disease: focus on everolimus-eluting stent (Xience V).
Synthesis in Vascular health and risk management, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed.
- Toward Lesion-specific Stenting Strategies: A Computational Framework to Validate the Deployment of Balloon-expandable Stents.Annals of biomedical engineering · 2026Article
- Article
- Research progress of absorbable stents.International journal of medical sciences · 2024Review
- Structural and temporal dynamics analysis on drug-eluting stents: History, research hotspots and emerging trends.Bioactive materials · 2023Review
- Novel usage of everolimus-eluting coronary stent for intracranial atherosclerotic disease: a technical report and case series.BMJ surgery, interventions, & health technologies · 2023Article
- Optimize PLA/EVA Polymers Blend Compositional Coating for Next Generation Biodegradable Drug-Eluting Stents.Polymers · 2022Article
- Evolutionary perspective of drug eluting stents: from thick polymer to polymer free approach.Journal of cardiothoracic surgery · 2022Review
- Article
- Intelligent H2S release coating for regulating vascular remodeling.Bioactive materials · 2021Article
- Vascular endothelial and smooth muscle cell galvanotactic response and differential migratory behavior.Experimental cell research · 2021Article
- Two-year safety and efficacy of Indigenous Abluminus Sirolimus Eluting Stent. Does it differ amongst diabetics? - Data from en-ABLe- REGISTRY.Journal of cardiovascular and thoracic research · 2021Article
- Inhibition of in-stent restenosis after graphene oxide double-layer drug coating with good biocompatibility.Regenerative biomaterials · 2019Article
- Comparison of the vessel healing process after everolimus-eluting stent and bare metal stent implantations in patients with ST-elevation myocardial infarction.Heart and vessels · 2019Observational
- In vitro and in vivo degradation of microfiber bioresorbable coronary scaffold.Journal of biomedical materials research. Part B, Applied biomaterials · 2018Article
- Comparison of Efficacy and Safety between First and Second Generation Drug-eluting Stents in Patients with Stable Coronary Artery Disease: A Single-center Retrospective Study.Chinese medical journal · 2017Article
- Early vascular responses after everolimus-eluting stent implantation assessed by serial observations of intracoronary optical coherence tomography.Heart and vessels · 2017Article
- Efficacy of everolimus-eluting stent implantation in patients with small coronary arteries (≤2.5 mm): outcomes of 3-year clinical follow-up.Heart and vessels · 2017Observational
- Rapamycin regulates macrophage activation by inhibiting NLRP3 inflammasome-p38 MAPK-NFκB pathways in autophagy- and p62-dependent manners.Oncotarget · 2017Article
- Undesired Outcomes of the Catania Stent Compared to the Xience Stent in Patients Undergoing Angioplasty: A Double-Blind Randomized Controlled Trial.Advanced biomedical research · 2017Article
- Potential therapeutic effects of mTOR inhibition in atherosclerosis.British journal of clinical pharmacology · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Percutaneous coronary revascularization has been a mainstay in the management of coronary artery disease since its introduction in the late 1970s. Bare-metal stents and, more recently, first-generation drug-eluting stents (DES), such as sirolimus-eluting (Cypher) and paclitaxel-eluting stents (Taxus), have further improved results of percutaneous coronary intervention (PCI) by improving early results and reducing the risk of restenosis. There is currently debate on the safety of these first-generation DES, given the potential for late stent thrombosis, especially after discontinuation of dual antiplatelet therapy. There are well known caveats on the performance of their respective metallic stent platforms, delivery, and dilation systems, and polymer coatings. Second-generation DES, such as zotarolimus-eluting (Endeavor) and everolimus-eluting stents (Xience V), have recently become available in the USA and/or Europe. The Xience V stent holds the promise of superior anti-restenotic efficacy as well as long-term safety. In addition, this stent is based on the Multi-link platform and delivery system. Recently available data already suggest the superiority of the Xience V stent in comparison to the Taxus stent in terms of prevention of restenosis, without significant untoward events. Nonetheless, the number of patients studied and the follow-up duration are still too limited to enable definitive conclusions. Only indirect meta-analyses can be used to date to compare the Xience V with the Cypher. This systematic review tries to provide a concise and critical appraisal of the data in support of the Xience V everolimus-eluting stent.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.